Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical stage specialty pharmaceutical company, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, which focuses on developing treatments for rare and orphan diseases, received official confirmation from Nasdaq's Listing Qualifications Department.
The achievement was marked by the company's ordinary shares maintaining a closing bid price of $1.00 or higher for 13 consecutive business days, meeting the criteria under Nasdaq Listing Rule 5550(a)(2). With this requirement satisfied, Nasdaq has formally closed the matter, ensuring Quoin's continued listing on the exchange.
Quoin Pharmaceuticals (NASDAQ: QNRX), un'azienda farmaceutica specializzata in fase clinica avanzata, ha riconquistato con successo la conformità al requisito minimo del prezzo di offerta di Nasdaq. La società, che si dedica allo sviluppo di trattamenti per malattie rare e orfane, ha ricevuto la conferma ufficiale dal Dipartimento di Qualificazione delle Quotazioni di Nasdaq.
Il risultato è stato raggiunto grazie al mantenimento di un prezzo di chiusura delle azioni ordinarie pari o superiore a 1,00 $ per 13 giorni lavorativi consecutivi, soddisfacendo così i criteri previsti dalla Regola 5550(a)(2) di Nasdaq. Con il requisito rispettato, Nasdaq ha formalmente chiuso la questione, garantendo la permanenza di Quoin nella quotazione.
Quoin Pharmaceuticals (NASDAQ: QNRX), una empresa farmacéutica especializada en etapa clínica avanzada, ha recuperado con éxito el cumplimiento del requisito mínimo del precio de oferta de Nasdaq. La compañía, que se enfoca en desarrollar tratamientos para enfermedades raras y huérfanas, recibió la confirmación oficial del Departamento de Calificación de Listados de Nasdaq.
Este logro se dio porque las acciones ordinarias de la empresa mantuvieron un precio de cierre de 1,00 $ o más durante 13 días hábiles consecutivos, cumpliendo con los criterios establecidos en la Regla 5550(a)(2) de Nasdaq. Con este requisito cumplido, Nasdaq cerró formalmente el caso, asegurando la continuidad de Quoin en la bolsa.
Quoin Pharmaceuticals (NASDAQ: QNRX)는 후기 임상 단계의 전문 제약회사로서 나스닥의 최저 입찰가 요건을 성공적으로 충족하였습니다. 희귀 및 고아 질환 치료제 개발에 중점을 둔 이 회사는 나스닥 상장 자격 부서로부터 공식 확인을 받았습니다.
이 성과는 회사의 보통주가 13거래일 연속으로 1.00달러 이상의 종가를 유지하여 나스닥 상장 규칙 5550(a)(2)의 기준을 충족함으로써 이루어졌습니다. 해당 요건이 충족됨에 따라 나스닥은 공식적으로 이 문제를 종료하고 Quoin의 상장 지속을 보장하였습니다.
Quoin Pharmaceuticals (NASDAQ : QNRX), une société pharmaceutique spécialisée en phase clinique avancée, a réussi à se conformer à l'exigence minimale du prix d'offre de Nasdaq. L'entreprise, qui se concentre sur le développement de traitements pour les maladies rares et orphelines, a reçu la confirmation officielle du département des qualifications de cotation de Nasdaq.
Cette réussite est marquée par le maintien du cours de clôture des actions ordinaires de la société à 1,00 $ ou plus pendant 13 jours ouvrables consécutifs, répondant ainsi aux critères de la règle de cotation Nasdaq 5550(a)(2). Avec cette exigence satisfaite, Nasdaq a officiellement clos le dossier, assurant la poursuite de la cotation de Quoin sur la bourse.
Quoin Pharmaceuticals (NASDAQ: QNRX), ein pharmazeutisches Spezialunternehmen in der späten klinischen Phase, hat erfolgreich die Einhaltung der Mindestgebotspreisvorgabe der Nasdaq wiedererlangt. Das Unternehmen, das sich auf die Entwicklung von Behandlungen für seltene und vernachlässigte Krankheiten spezialisiert hat, erhielt die offizielle Bestätigung von der Listing Qualifications Abteilung der Nasdaq.
Der Erfolg wurde dadurch markiert, dass die Stammaktien des Unternehmens an 13 aufeinanderfolgenden Handelstagen einen Schlussgebotspreis von 1,00 $ oder höher aufwiesen und somit die Kriterien gemäß Nasdaq Listing Rule 5550(a)(2) erfüllten. Mit Erfüllung dieser Vorgabe hat Nasdaq die Angelegenheit formell abgeschlossen und die fortgesetzte Notierung von Quoin an der Börse sichergestellt.
- Regained Nasdaq compliance by maintaining $1.00+ share price for 13 consecutive days
- Removal of delisting risk from Nasdaq
- None.
Insights
Quoin's regained Nasdaq compliance removes delisting risk, preserving market access and investor confidence—crucial for a late-stage pharmaceutical company.
Quoin Pharmaceuticals has successfully navigated a significant regulatory challenge by regaining compliance with Nasdaq's minimum bid price requirement. The company received formal confirmation that its shares maintained a closing price above
This development eliminates a critical risk factor that threatened Quoin's continued presence on a major exchange. When companies fail to maintain Nasdaq listing requirements, they face potential delisting—typically resulting in reduced trading liquidity, diminished institutional investor interest, and restricted access to capital markets.
For a late-stage pharmaceutical company focused on rare and orphan diseases like Quoin, maintaining its Nasdaq listing is particularly crucial. Such companies typically require substantial capital infusions to fund clinical development programs and regulatory approval processes. A Nasdaq listing provides significantly better access to capital markets and a broader investor base compared to alternatives like over-the-counter exchanges.
With this compliance issue resolved, management can redirect full attention to their core operations and clinical programs without the distraction of addressing listing deficiencies. The consistent trading above the threshold also indicates a baseline of market support for the company's shares.
While this news resolves an existential threat rather than representing a new positive catalyst, it removes a significant overhang that likely constrained investor interest in the stock.
ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
The notification from Nasdaq confirms that for the last 13 consecutive business days, the closing bid price of the Company’s ordinary shares was at or above
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,” “anticipate,” “look forward,” “believe,” “may,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to deliver a safe and effective treatment for Netherton Syndrome; whether the Company’s studies successfully generate data that is sufficiently robust and comprehensive to support an NDA filing for QRX003 as an approved treatment for Netherton Syndrome; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
What minimum bid price did QNRX need to meet for Nasdaq compliance in 2025?
How long did Quoin Pharmaceuticals (QNRX) maintain the required stock price for Nasdaq compliance?
What happens now that QNRX has regained Nasdaq compliance?
What is Quoin Pharmaceuticals' main business focus as of 2025?
When did Quoin Pharmaceuticals receive Nasdaq compliance confirmation?
